EDITEditas Medicine, Inc.

$260M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-7.0% YoY

Gross Profit

-$50M-438.6% margin

Operating Income

-$66M-576.9% margin

Net Income

-$62M-547.3% margin

EPS (Diluted)

$-1.00

QoQ Revenue Growth

-81.8%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$41M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$573M

Total Liabilities

$179M

Stockholders' Equity

$394M

Cash & Equivalents

$140M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$12M	-7.0%
Gross Profit	-$50M	-$23M	-122.6%
Operating Income	-$66M	-$39M	-67.1%
Net Income	-$62M	-$38M	-65.5%

EDIT Q4 2020 Earnings — Editas Medicine, Inc. Revenue & Financial Results | Market Cap Arena